Theriva Biologics — Third Quarter 2026 Earnings Summary

Theriva Biologics reported third-quarter 2026 financial results showing cash and cash equivalents of $8.5 million with a projected runway into the first quarter of 2027. The company completed the sale of its SYN-004 antibiotic-degrading enzyme portfolio to Biossil Labs Inc. for a $350,000 upfront payment and up to $91 million in potential milestones and royalties. Clinical progress includes ongoing enrollment in the VIRAGE2 Phase 2a trial for VCN-01 in metastatic pancreatic ductal adenocarcinoma, with enrollment expected to conclude in the fourth quarter of 2026. Additionally, detailed analyses of the VIRAGE Phase 2b trial data were published in Nature Medicine, demonstrating improved survival outcomes for patients treated with VCN-01 combined with chemotherapy.